The Medicines Co

📅 Upcoming

🕒 Recent(90d)

News

• Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
  The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.
  biopharma_dive · 5d ago
• The molecule was fine. The moment wasn’t.
  Some overlooked medicines aren’t failures. They just arrived before the market was ready.
  biopharma_dive · 14d ago
• Euro Roundup: EMA seeks feedback on platform trials; MHRA to recognize CE-marked devices indefinitely
  The European Medicines Agency (EMA) is holding a consultation into the methodological aspects of confirmatory platform clinical trials.
  raps · 19d ago
• Most new drugs are still too costly at launch, ICER says
  A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.
  biopharma_dive · 20d ago
• Should amylin have been obesity therapeutics’ primary target from the start?
  While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 year…
  biospace · 22d ago
• Iambic CEO on taking an AI drug company public
  Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.
  biopharma_dive · 24d ago
• Euro Roundup: EMA to make ACT EU permanent in 2027
  In January, the European Medicines Agency (EMA) will make permanent a pilot project that helps sponsors prepare clinical trial applications.
  raps · 26d ago
• Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business
  With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure.
  biospace · 1mo ago
• STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few
  Exon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.
  stat · 1mo ago
• EMA plans major update to pharmacogenomics guideline
  The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) is planning to update a 2018 guideline on good pharmacogenomic practices. While the guideline is less tha…
  raps · 1mo ago